RU2015149771A - Противоопухолевое средство - Google Patents

Противоопухолевое средство

Info

Publication number
RU2015149771A
RU2015149771A RU2015149771A RU2015149771A RU2015149771A RU 2015149771 A RU2015149771 A RU 2015149771A RU 2015149771 A RU2015149771 A RU 2015149771A RU 2015149771 A RU2015149771 A RU 2015149771A RU 2015149771 A RU2015149771 A RU 2015149771A
Authority
RU
Russia
Prior art keywords
tumor
therapeutic
compounds
antitumor agent
prophylactic agent
Prior art date
Application number
RU2015149771A
Other languages
English (en)
Other versions
RU2667644C2 (ru
Inventor
Масао СУГАМАТА
Original Assignee
Тотиги Инститьют Оф Клиникал Патолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тотиги Инститьют Оф Клиникал Патолоджи filed Critical Тотиги Инститьют Оф Клиникал Патолоджи
Publication of RU2015149771A publication Critical patent/RU2015149771A/ru
Application granted granted Critical
Publication of RU2667644C2 publication Critical patent/RU2667644C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (3)

1. Терапевтическое или профилактическое средство (исключая средство, подавляющее метастазирование), для злокачественной опухоли(ей), которое содержит по меньшей мере один ингибитор лейкотриена, выбранный из группы, состоящей из: соединений, выбранных из монтелукаста, зафирлукаста и пранлукаста; фармацевтически приемлемых солей указанных соединений; и фармацевтически приемлемых сольватов указанных соединений и указанных солей.
2. Терапевтическое или профилактическое средство по п. 1, где указанная опухоль представляет собой солидную опухоль(и).
3. Терапевтическое или профилактическое средство по п. 1 или 2, где указанная опухоль представляет собой солидную злокачественную опухоль(и).
RU2015149771A 2013-04-22 2014-04-22 Противоопухолевое средство RU2667644C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013-089356 2013-04-22
JP2013/089356 2013-04-22
JP2013089356 2013-04-22
PCT/JP2014/061264 WO2014175253A1 (ja) 2013-04-22 2014-04-22 抗腫瘍剤

Publications (2)

Publication Number Publication Date
RU2015149771A true RU2015149771A (ru) 2017-05-26
RU2667644C2 RU2667644C2 (ru) 2018-09-21

Family

ID=51791825

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015149771A RU2667644C2 (ru) 2013-04-22 2014-04-22 Противоопухолевое средство

Country Status (8)

Country Link
US (3) US9775836B2 (ru)
EP (1) EP2990056A4 (ru)
JP (2) JP5858391B2 (ru)
KR (1) KR102356955B1 (ru)
CN (3) CN110575542A (ru)
IL (2) IL242179A (ru)
RU (1) RU2667644C2 (ru)
WO (1) WO2014175253A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990056A4 (en) 2013-04-22 2016-12-14 Tochigi Inst Of Clinical Pathology ANTITUMOR AGENT
JP7272655B2 (ja) * 2017-01-30 2023-05-12 ウェスタン ニュー イングランド ユニバーシティ チオールイソメラーゼ阻害剤およびその使用
WO2019109147A1 (en) * 2017-12-06 2019-06-13 Omara Stephen Kenneth Methods of treating cancer with leukotriene receptor antagonists
RU2700410C1 (ru) * 2019-05-20 2019-09-17 Федеральное государственное бюджетное учреждение науки "Национальный научный центр морской биологии им. А.В. Жирмунского" Дальневосточного отделения Российской академии наук (ННЦМБ ДВО РАН) Метод иммуноокрашивания биологического материала для конфокальной микроскопии

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532675A (ja) * 2000-05-09 2003-11-05 クレイトン ユニバーシティ 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法
JP2003252763A (ja) 2002-02-27 2003-09-10 Yuichiro Kamikawa 抗腫瘍剤
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
CN101119731A (zh) * 2003-07-31 2008-02-06 埃匹吉尼斯医药有限公司 用于治疗哮喘或慢性阻塞性肺病的脱氢表雄酮或硫酸脱氢表雄酮与白三烯受体拮抗剂的组合物
US20050026882A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
JP3983272B2 (ja) * 2004-07-14 2007-09-26 有限会社 炎症研究所 腫瘍転移の抑制方法
EP1863450A1 (en) * 2005-03-16 2007-12-12 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
WO2008105803A1 (en) * 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
WO2010115593A2 (en) * 2009-04-03 2010-10-14 Fraunhofer Gesellschaft Zur Förderung Der Angewandten Forschung E. V. Novel targets for the diagnosis and treatment of dysplasia
FR2984230B1 (fr) * 2011-12-16 2014-04-25 Michelin Soc Tech Bandage pneumatique avec une bande de roulement comportant un feutre
EP2990056A4 (en) * 2013-04-22 2016-12-14 Tochigi Inst Of Clinical Pathology ANTITUMOR AGENT

Also Published As

Publication number Publication date
US10729683B2 (en) 2020-08-04
JP2016094403A (ja) 2016-05-26
JPWO2014175253A1 (ja) 2017-02-23
KR20160018493A (ko) 2016-02-17
US20170348299A1 (en) 2017-12-07
KR102356955B1 (ko) 2022-01-28
CN105307682A (zh) 2016-02-03
EP2990056A1 (en) 2016-03-02
IL245157A0 (en) 2016-06-30
JP6558757B2 (ja) 2019-08-14
US20160058748A1 (en) 2016-03-03
US10149846B2 (en) 2018-12-11
US20190070163A1 (en) 2019-03-07
EP2990056A4 (en) 2016-12-14
CN110575542A (zh) 2019-12-17
CN110559441A (zh) 2019-12-13
RU2667644C2 (ru) 2018-09-21
CN105307682B (zh) 2020-10-02
JP5858391B2 (ja) 2016-02-10
US9775836B2 (en) 2017-10-03
IL242179A (en) 2016-05-31
WO2014175253A1 (ja) 2014-10-30

Similar Documents

Publication Publication Date Title
IL267773B (en) A process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
IL254720A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
EP3414224A4 (en) INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
EA201790630A1 (ru) Способы получения рибозидов
EA201791046A1 (ru) Макроциклические пептиды, используемые в качестве иммуномодуляторов
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201591913A1 (ru) Ингибиторы протеинкиназы
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201600091A1 (ru) 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов
EA201790661A3 (ru) Ингибиторы вируса гепатита c
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
RU2016146119A (ru) Новый кристалл тетрациклического соединения
EA201792021A1 (ru) Ингибитор jak
MA40170A (fr) Dérivés hétérocycliques de morphinan et leur utilisation
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EA201592183A1 (ru) Ингибиторы bace
RU2015149771A (ru) Противоопухолевое средство
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
RS54716B1 (en) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS
MD3395821T2 (ro) Compuși antitumorali
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.